CDTX on NASDAQ

Cidara Therapeutics

Logo: cidara.com4

We are a biotechnology company using our proprietary Cloudbreak ® platform to develop drug-Fc conjugate, or DFC, immunotherapies designed to save lives and improve the standard of care for patients.6 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2013Founded1

Compare with Inhibrx Biosciences, Inc., Scinai Immunotherapeutics Ltd. or SAB Biotherapeutics, Inc., or pick any stock.

  • TickerCDTX on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersSan Diego1
  • Websitewww.cidara.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address6310 Nancy Ridge Drive, Suite 101, San Diego, Ca 921215
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300IHQ9Z7RI1X2D223
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 52513633

See how the biggest companies compare on our leaderboards

Cidara Therapeutics image from its website
Image: cidara.com4

We are a biotechnology company using our proprietary Cloudbreak ® platform to develop drug-Fc conjugate, or DFC, immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-13811.9%Operating margin7
-13319.8%Net margin7
-70.6%Revenue growth, 20247
-104.0%Return on equity7
-$176.7MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development100¢$71.9M

Out of $1.3M in revenue.7 The company lost money this year.

Financial statements

Revenue87$1.3M in 2024
0$2.0M$4.0M$6.0M2022: $0$020222023: $4.3M$4.3M20232024: $1.3M$1.3M2024−71%
Operating income9101187-$176.1M in 2024+178% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$63.3M-$63.3M20182019: -$41.7M-$41.7M2019−34%2020: -$71.8M-$71.8M2020+72%2021: -$42.3M-$42.3M2021−41%2022: -$33.5M-$33.5M2022−21%2023: -$27.1M-$27.1M2023−19%2024: -$176.1M-$176.1M2024+551%
Net income9101187-$169.8M in 2024+188% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$59.0M-$59.0M20182019: -$41.1M-$41.1M2019−30%2020: -$72.1M-$72.1M2020+75%2021: -$42.5M-$42.5M2021−41%2022: -$33.6M-$33.6M2022−21%2023: -$22.9M-$22.9M2023−32%2024: -$169.8M-$169.8M2024+641%
Fiscal year2018201920202021202220232024
Revenue$08$4.3M8$1.3M7
Research and development$49.1M9$46.4M10$68.0M11$73.1M11$77.4M8$36.8M7$71.9M7
Selling, general and admin$20.5M8$18.3M8
Operating expenses$91.8M11$98.0M8$50.3M7$177.4M7
Operating income-$63.3M9-$41.7M10-$71.8M11-$42.3M11-$33.5M8-$27.1M7-$176.1M7
Income before tax-$42.5M11-$33.3M8-$25.1M7-$170.3M7
Income tax$09$010$011$011$272.0K8$15.0K7$07
Net income-$59.0M9-$41.1M10-$72.1M11-$42.5M11-$33.6M8-$22.9M7-$169.8M7
Earnings per share-$1.3710-$1.8011-$0.8111-$0.488-$5.257-$26.757
Earnings per share (diluted)-$1.3710-$1.8011-$0.8111-$0.488-$5.257-$26.757
Shares (weighted, basic)69.9M shares84.4M shares76.3M shares7
Shares (weighted, diluted)52.5M shares1169.9M shares84.4M shares76.3M shares7

Compare Cidara Therapeutics with another company

Leadership

Who has led Cidara Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Kevin Forrest2015–2016
  2. Matthew Onaitis2016–2018
  3. James E. Levine2018–2021
  4. Preetam Shah2021–2025
  5. Frank Karbe2025–now

Chief operating officer

  1. Kevin Forrest2015–2016
  2. Paul Daruwala2018–2022
  3. Shane Ward2023–now
201520202025
Board members and other officers (30)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorJeffrey Stein, Ph.D. named May 6, 202451
  • Executive OfficerLeslie R. Tari, Ph.D. named May 6, 202451
  • Executive OfficerPreetam R. Shah, Ph.D. named May 6, 202451
  • DirectorBonnie R. Bassler, Ph.D. named May 6, 202451
  • DirectorJames R. Merson, Ph.D. named May 6, 202451
  • DirectorLaura R. Tadvalkar, Ph.D. named May 6, 202451

Former names

  • K2 THERAPEUTICS, INC.Jun 17, 2014 to Feb 4, 20155

Timeline

  1. 2013Founded Founded1

Filings

362 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 61 major events, 140 insider forms, 51 large holders, 1 private raises, 92 other. The latest 20:

  1. Feb 17, 2026SCHEDULE 13G/A EDGAR
  2. Feb 17, 2026SCHEDULE 13G/A EDGAR
  3. Feb 13, 2026SCHEDULE 13G/A EDGAR
  4. Jan 30, 2026SCHEDULE 13G EDGAR
  5. Jan 20, 202615-12G EDGAR
  6. Jan 9, 2026EFFECT EDGAR
  7. Jan 9, 2026EFFECT EDGAR
  8. Jan 9, 2026EFFECT EDGAR
  9. Jan 9, 2026EFFECT EDGAR
  10. Jan 9, 2026EFFECT EDGAR
  11. Jan 9, 2026EFFECT EDGAR
  12. Jan 9, 2026SCHEDULE 13D/A EDGAR
  13. Jan 9, 20264 EDGAR
  14. Jan 7, 20264 EDGAR
  15. Jan 7, 20264 EDGAR
  16. Jan 7, 20264 EDGAR
  17. Jan 7, 20264 EDGAR
  18. Jan 7, 20264 EDGAR
  19. Jan 7, 20264 EDGAR
  20. Jan 7, 20264 EDGAR

The 362 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

35 open-market trades by officers, directors and large owners since October 2021: 9 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 10, 2025Ward ShaneCOO & CLOSale9,959$220.08$2.2MForm 4
Sep 11, 2025Davarpanah Nicole NegarChief Medical OfficerSale474$62.86$29.8KForm 4
Jun 26, 2025Kolchinsky PeterDirectorBuy2,272,727$44.00$100.0MForm 4
Jun 3, 2025Mineo ChrysaDirectorBuy1,050$23.44$24.6KForm 4
Jun 2, 2025Mineo ChrysaDirectorBuy2,270$21.71$49.3KForm 4
Mar 11, 2025Ward ShaneCOO & CLOSale1,664$21.96$36.5KForm 4
Mar 11, 2025Tari LeslieCHIEF SCIENTIFIC OFFICERSale1,773$21.96$38.9KForm 4
Sep 11, 2024Sandison TaylorChief Medical OfficerSale924$11.64$10.8KForm 4
Sep 11, 2024Tari LeslieCHIEF SCIENTIFIC OFFICERSale909$11.64$10.6KForm 4
Jun 7, 2024Stein JeffreyPresident & CEOBuy8,000$13.21$105.7KForm 4
Mar 11, 2024Tari LeslieCHIEF SCIENTIFIC OFFICERSale21,029$0.67$14.1KForm 4
Mar 11, 2024Sandison TaylorChief Medical OfficerSale20,662$0.67$13.8KForm 4
Mar 11, 2024Ward ShaneCOO & CLOSale20,473$0.67$13.7KForm 4
Mar 11, 2024Shah PreetamChief Financial OfficerSale18,931$0.67$12.7KForm 4
Sep 11, 2023Tari LeslieCHIEF SCIENTIFIC OFFICERSale18,469$0.95$17.5KForm 4
Sep 11, 2023Sandison TaylorChief Medical OfficerSale18,793$0.95$17.9KForm 4
Aug 14, 2023Tari LeslieCHIEF SCIENTIFIC OFFICERBuy10,000$0.97$9.7KForm 4
Aug 8, 2023Stein JeffreyPresident & CEOBuy50,000$0.96$48.0KForm 4
Mar 27, 2023Stein JeffreyPresident & CEOBuy50,000$1.04$52.0KForm 4
Mar 13, 2023Ward ShaneCOO & CLOSale4,329$1.53$6.6KForm 4

All 35 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 24, 2024Raised $240 million in a private offering of equity Form D: 7 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68